Concord Biotech Q2 profit slides 34%; board clears new ventures

Concord Biotech also reported drops in revenue, EBITDA and margins for Q2FY26. Shares of Concord Biotech Ltd ended marginally higher on Thursday, November 13, up 0.04% at ₹1,463.80 on the NSE.

Source link